Biosensor
Biosensor is an analytical device that combines a biological recognition element — such as an enzyme, antibody, nucleic acid, or whole cell — with a physicochemical transducer to convert a biological input into a measurable signal. The output is typically electrical, optical, or thermal in nature, and can be quantified to determine the presence or concentration of a target substance. Originally developed for clinical diagnostics, biosensor technology has expanded dramatically into military, environmental, and — according to a growing body of researchers — covert surveillance applications. The convergence of biosensors with nanotechnology, wireless communication, and the Internet of Bodies has raised serious questions about undisclosed deployment of biosensing components via pharmaceutical products and the implications for bodily autonomy and population-level biological monitoring.
How a Biosensor Works
A biosensor consists of two core components:
- Biological recognition element — a molecule or living system that selectively binds to or reacts with the target analyte. Common examples include enzymes (which catalyse a reaction), antibodies (which bind antigens), aptamers (synthetic nucleic acids that bind target molecules), and whole cells or tissues.
- Transducer — converts the biological response into a measurable physicochemical signal. Transducers may be electrochemical, optical, piezoelectric, or thermal.
The signal produced is amplified, processed, and read out — either locally or transmitted wirelessly to an external device.
Types of Biosensors
Electrochemical
The most widely deployed type. Electrochemical biosensors measure the electrical change produced by a biochemical reaction at an electrode surface. Amperometric sensors measure current; potentiometric sensors measure voltage; impedimetric sensors measure changes in electrical impedance. The standard blood glucose monitor is an amperometric electrochemical biosensor. Graphene-based materials have become a favoured electrode substrate due to their extraordinary surface area, electrical conductivity, and biocompatibility — properties that also make them candidates for nano-scale, in-body deployment.
Optical
Optical biosensors use changes in light properties — absorption, fluorescence, surface plasmon resonance — to detect biological events. Surface plasmon resonance (SPR) biosensors are widely used in pharmaceutical research to study protein interactions. Fluorescent optical biosensors can be engineered to operate inside living cells.
Piezoelectric
Piezoelectric biosensors detect mass changes on a crystal surface caused by analyte binding. Quartz crystal microbalance (QCM) devices can detect binding events at nanogram sensitivity. These are used in pathogen detection and environmental monitoring.
Thermal (Calorimetric)
Calorimetric biosensors measure the heat released or absorbed during a biochemical reaction. They are particularly useful where enzymatic reactions are involved. Although less common in consumer devices, they have applications in industrial fermentation monitoring and point-of-care diagnostics.
Medical and Research Applications
Mainstream biosensor applications are well-documented and span a wide range of clinical and research contexts:
- Continuous Glucose Monitors (CGMs) — subcutaneous electrochemical biosensors that continuously sample interstitial glucose levels and transmit data wirelessly to a smartphone or receiver. Devices such as the Dexcom G7 and Abbott FreeStyle Libre represent mass-market implantable biosensor platforms already operating inside tens of millions of human bodies.
- Implantable Cardiac Monitors (ICMs) — small devices inserted under the skin to continuously monitor cardiac rhythm for up to three years, transmitting data remotely to clinical systems.
- Lab-on-Chip — miniaturised biosensor arrays integrated onto a single microchip capable of performing multiple simultaneous assays from a tiny fluid sample. These underpin rapid diagnostic tests and are being developed for battlefield triage and remote population screening.
- Point-of-Care (POC) diagnostics — biosensor strips and cartridges used in emergency rooms, GP surgeries, and field environments for rapid detection of pathogens, cardiac markers, and drug levels.
- Environmental monitoring — biosensors deployed in water systems, soil, and air to detect pollutants, pathogens, or chemical agents.
DARPA and Military Biosensor Research
The Defense Advanced Research Projects Agency has invested heavily in biosensor development for military and intelligence applications, often with implications extending well beyond the battlefield.
DARPA Persistent Aquatic Living Sensors (PALS)
Launched in 2018, the PALS programme sought to exploit the natural sensing capabilities of marine organisms — fish, crustaceans, molluscs — as persistent environmental biosensors. The premise was that living organisms respond to underwater stimuli (submarines, divers, vessels) in ways that can be monitored and decoded. DARPA researchers aimed to develop interfaces capable of reading these biological responses and transmitting them as actionable intelligence. PALS represents a broader DARPA philosophy: that living organisms are more sensitive, more energy-efficient, and more adaptable than man-made sensors for certain detection tasks.
Other DARPA Biosensor Initiatives
- Electrical Prescriptions (ElectRx) — a DARPA programme developing ultra-miniature implantable biosensors and neurostimulators to monitor and modulate peripheral nerve function, ostensibly for treating disease, but developing core technology for closed-loop biological monitoring and intervention.
- Biochronicity — research into biological timing mechanisms and circadian rhythm monitoring as biosensor signals.
- In Vivo Nanoplatforms (IVN) — seeking to develop nanoparticle-based systems capable of residing within the body and sensing physiological or chemical changes, reporting wirelessly.
- Soldier-worn and implantable biosensors for real-time monitoring of combat stress hormones, blood chemistry, hydration, and wound status have been actively developed through DARPA Human Enhancement Programmes.
The Department of Defence has explicitly framed in-body biosensors as force-multipliers, enabling real-time physiological awareness of troops. Critics note that the same technology, once developed, is available for broader population application.
Nano-Biosensors: The In-Body Frontier
The miniaturisation of biosensors to the nanoscale has transformed what is technically possible for in-body deployment. A nano-biosensor may be as small as tens of nanometres — well within the size range of particles deliverable by injection, inhalation, or transdermal absorption.
Key developments in nano-biosensor technology include:
- Carbon nanotube biosensors — single-walled carbon nanotubes (SWCNTs) functionalised with biological recognition molecules can operate inside living cells, detecting specific analytes by near-infrared fluorescence that passes through biological tissue.
- Quantum dot biosensors — semiconductor nanocrystals used as optical labels for biosensing within cells and tissues.
- DNA nanotechnology biosensors — engineered DNA structures that act as molecular switches, reconfiguring in the presence of a target analyte and producing a detectable signal.
- Graphene Oxide biosensors — graphene oxide and reduced graphene oxide have become the substrate of choice for nano-electrochemical biosensors due to their high surface area, ease of functionalisation, and electrical properties. Research published in peer-reviewed literature demonstrates graphene-oxide-based electrochemical biosensors capable of detecting nucleic acids, proteins, and small molecules at femtomolar concentrations.
According to researchers including Dr. Ana Maria Mihalcea and the team at La Quinta Columna, structures consistent with graphene-based electrochemical biosensors have been identified in live blood analysis of individuals who received COVID-19 vaccines. These claims remain contested by mainstream bodies but have prompted independent investigation into whether injectable pharmaceutical products could serve as covert delivery mechanisms for nano-biosensor components.
The Human Body as a Sensor Platform
The Internet of Bodies (IoB) framework — explicitly discussed in academic and policy literature including papers from the RAND Corporation — envisions the human body as a networked sensor node. In this framework:
- Implanted and ingested biosensors continuously sample physiological parameters
- Data is transmitted via Body Area Network and Body Sensor Network protocols to edge devices (smartphones, wearables) and thence to cloud infrastructure
- Aggregated biological data feeds into population health monitoring, behavioural prediction, and — according to critics — social control systems
The MICS Band (Medical Implant Communications Service), operating at 402–405 MHz, is the designated spectrum for implanted biosensor telemetry. This band is specifically regulated for low-power transmission from inside the body, confirming that regulatory and technical infrastructure for in-body biosensor networks already exists.
The Intra-Body Nano Network concept extends this further: if nano-biosensors are deployed in sufficient density within the body, they could form a self-organising mesh network capable of routing biosensor data outward via a gateway device without the subject's awareness or consent.
Biosurveillance at Population Scale
When biosensor data from millions of individuals is aggregated, the surveillance implications become qualitatively different from any previous monitoring technology:
- Real-time physiological state of populations — stress levels, immune responses, neurochemical states — could be monitored continuously
- Anomalous readings could flag individuals for automated intervention or targeting
- Biological data could be correlated with location, communication, and behavioural data to build comprehensive profiles
Biosurveillance programmes at national level — including those coordinated through the WHO and national public health agencies — are already frameworks for population biological monitoring. Critics such as Catherine Austin Fitts argue that the convergence of nano-biosensors, digital identity systems, and financial infrastructure is not coincidental but represents a coherent architecture of control aligned with the Transhumanist Agenda.
Concerns About Undisclosed Deployment
Several researchers have raised specific concerns about biosensor components potentially present in injectable and other pharmaceutical products without disclosure:
- Ricardo Delgado and Dr. Pablo Campra of La Quinta Columna published microscopy analysis of COVID-19 vaccine vials claiming to identify graphene oxide structures. Graphene oxide is a core substrate for electrochemical biosensors.
- Mik Andersen (pseudonym, researcher Corona2Inspect) published detailed technical analysis suggesting that self-assembling nanostructures observed in vaccine preparations correspond to described components of intra-body nano-network architectures, including biosensor-like elements.
- Dr. Ana Maria Mihalcea has documented structures in live blood analysis that she describes as consistent with nanotechnology including potential biosensing components, present in both vaccinated and, increasingly, unvaccinated individuals — suggesting possible environmental or aerosol exposure pathways.
These claims are not validated by regulatory bodies. However, given the documented existence of graphene-based biosensor technology in the peer-reviewed literature, the regulatory approval of nano-containing formulations, and the DARPA investment in in-body sensor platforms, researchers argue the technical plausibility cannot be dismissed.
Connection to Targeted Individuals
Targeted Individuals frequently report physiological symptoms and monitoring experiences consistent with what would be expected if in-body biosensors were active and being used to guide directed interventions:
- Awareness of being physiologically monitored
- Correlation between physical symptoms and external stimuli
- Reports of biological data apparently being accessed by third parties
- Symptoms consistent with remote physiological modulation based on biosensor feedback
Remote Neural Monitoring and Remote Neural Modulation technologies, as described by researchers including Dr. Robert Duncan, imply closed-loop systems in which biosensor feedback informs and adjusts the targeting signal — a system that would require precisely the kind of in-body biosensor platform described in DARPA literature.
See Also
- Internet of Bodies
- Body Sensor Network
- Body Area Network
- MICS Band
- Intra-Body Nano Network
- Graphene Oxide
- Nanotechnology
- Biosurveillance
- DARPA
- DARPA Human Enhancement Programmes
- Targeted Individuals
- Transhumanist Agenda
- COVID Vaccines
- La Quinta Columna
- Dr. Ana Maria Mihalcea
- Remote Neural Monitoring
References
- Thévenot, D.R. et al. (2001). "Electrochemical biosensors: recommended definitions and classification." Biosensors and Bioelectronics, 16(1–2), 121–131.
- DARPA PALS Programme Solicitation (2018). Persistent Aquatic Living Sensors. DARPA Biological Technologies Office.
- RAND Corporation (2020). The Internet of Bodies: Opportunities, Risks, and Governance.
- Andersen, M. [Corona2Inspect] (2021). "Identification of possible nano-network components in COVID-19 vaccines." Independent research publication.
- Campra, P. (2021). "Detection of graphene in COVID-19 vaccines by Micro-Raman Spectroscopy." University of Almería.
